2.0
Mar 10, 2016
Former employee
Recommend
CEO approval
Business Outlook
Pros
Good people who care about their patients' needs. Baxter's portfolio represents a wide range of products that perform well. The new CEO, Jose Almeida, should be a breath of fresh air with regard to strategic direction & decisive action.
Cons
Previously Baxter was very bureaucratic, slow & indecisive. Their clinical studies were ill-conceived, slow, poorly managed & very expensive.